trending Market Intelligence /marketintelligence/en/news-insights/trending/fzf2T92H5S-lRnHHKxmRjQ2 content esgSubNav
In This List

Sandu Pharmaceuticals fiscal Q3 profit climbs 94.4% YOY

Podcast

Next in Tech | Episode 50: InfoSec spending up, again…

Blog

Broadcast deal market recap 2021

Podcast

Next in Tech | Episode 49: Carbon reduction in cloud

Blog

Volume of Investment Research Reports on Inflation Increased in Q4 2021


Sandu Pharmaceuticals fiscal Q3 profit climbs 94.4% YOY

Sandu Pharmaceuticals Ltd. said its normalized net income for the fiscal third quarter ended Dec. 31, 2014, was 25 Indian paise per share, an increase of 92.3% from 13 paise per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was 1.7 million rupees, a gain of 94.4% from 893,750 rupees in the year-earlier period.

The normalized profit margin increased to 1.7% from 1.0% in the year-earlier period.

Total revenue climbed 10.9% year over year to 101.7 million rupees from 91.7 million rupees, and total operating expenses rose 8.9% year over year to 96.0 million rupees from 88.2 million rupees.

Reported net income rose 83.2% year over year to 2.0 million rupees, or 29 paise per share, from 1.1 million rupees, or 16 paise per share.

As of Jan. 15, US$1 was equivalent to 61.77 Indian rupees.